Non-Viral Drug Delivery Systems Market Forecast Highlights Expansion From $11.25 Billion To $19.07 Billion Through 2030
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Non-Viral Drug Delivery Systems Market CAGR Analysis And Future Market Development
The non-viral drug delivery systems market has experienced substantial expansion in recent times, with its valuation rising from $9.84 billion in 2025 to an expected $11.26 billion by 2026, reflecting a compound annual growth rate (CAGR) of 14.4%. This upward trajectory during the historical period has been driven by factors such as a continued dependence on viral delivery methods, a relatively low level of awareness regarding non-viral alternatives, the ongoing development of emerging biologics, the establishment of early-stage regulatory frameworks for drug delivery, and a initial academic research emphasis on nanoparticles.
The market for non-viral drug delivery systems is projected to experience rapid expansion in the coming years. By 2030, its value is anticipated to reach $19.07 billion, reflecting a compound annual growth rate (CAGR) of 14.1%. Forecasted growth is driven by several factors, including progress in polymer-based carriers, the expansion of RNA and DNA therapeutics, rising funding for personalized medicine, growth in contract development and manufacturing organizations (CDMOs), and strengthened partnerships between pharmaceutical firms and academic institutions. Key developments expected during this period include increased use of non-viral delivery platforms for targeted therapies, expanded application of nanoparticles and liposome-based carriers, efforts to minimize immune responses while boosting safety, further advancement of personalized medicine and targeted treatments, and continued growth in CDMO operations and academic research collaborations.
Download A Free Sample Report For Comprehensive Market Insights:
Non-Viral Drug Delivery Systems Market Expansion Drivers: What Is Shaping Future Growth?
The growing interest in tailored therapeutics is anticipated to boost the non-viral drug delivery systems market in the coming period. Personalized medicine, a healthcare strategy that customizes treatment based on an individual’s genetic profile, lifestyle, and environmental factors, is experiencing heightened demand because it enables more targeted and effective interventions for each patient’s unique disease causes. Non-viral drug delivery platforms support this approach by facilitating the safe transfer of drugs or genetic material into cells, thereby minimizing risks and enhancing treatment accuracy. A case in point is provided by the Personalized Medicine Coalition, a U.S.-based nonprofit organization, which reported in February 2024 that the FDA approved 16 new personalized therapies for rare diseases in 2023, a substantial rise from just 6 approvals in 2022. Consequently, the rising demand for personalized medicine is propelling the expansion of the non-viral drug delivery systems market.
Non-Viral Drug Delivery Systems Market Segment Landscape: Which Areas Lead Market Development?
The non-viral drug delivery systems market covered in this report is segmented –
1) By Type Of Molecule Delivered: Biologics, Small Molecules
2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics
Subsegments:
1) By Biologics: Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
2) By Small Molecules: Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs
Non-Viral Drug Delivery Systems Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Leading players in the non-viral drug delivery system market are increasingly prioritizing cutting-edge technologies like pre-optimized ionizable lipid mix systems to accelerate the creation and deployment of RNA-based treatments. This formulation technology facilitates the effective enclosure of RNA molecules within lipid nanoparticles, offering enhanced stability, secure payload transport, and precise delivery for gene-targeted therapies. As an example, in September 2024, Cytiva, a biotechnology firm based in the United States, introduced an RNA delivery LNP kit designed for use with its NanoAssemblr Ignite and Ignite+ platforms. The system contains a pre-formulated ionizable lipid mix that enables quick testing of RNA compounds and efficient verification of delivery efficacy, particularly for developing vaccines against infectious diseases. It operates seamlessly with automated microfluidic devices, supports consistent large-scale production using GMP-certified materials, and provides step-by-step instructions along with supporting data to guide researchers from initial exploration through clinical assessment.
Non-Viral Drug Delivery Systems Market Industry Leaders And Market Competition
Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.
Access The Complete Non-Viral Drug Delivery Systems Market Report:
Non-Viral Drug Delivery Systems Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the non-viral drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
